{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:16:53Z","timestamp":1790716613520,"version":"4.1.0"},"reference-count":229,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.lfs.2020.117843","type":"journal-article","created":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T20:32:31Z","timestamp":1590438751000},"page":"117843","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["The role of metabolic diseases in cardiotoxicity associated with cancer therapy: What we know, what we would know"],"prefix":"10.1016","volume":"255","author":[{"given":"Serena","family":"L'Abbate","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Kusmic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2020.117843_bb0005","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/annonc\/mdq295","volume":"21","author":"Brana","year":"2010","journal-title":"Cardiotoxicity. Ann. Oncol."},{"key":"10.1016\/j.lfs.2020.117843_bb0010","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.yjmcc.2012.03.006","article-title":"Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies","volume":"52","author":"Octavia","year":"2012","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.lfs.2020.117843_bb0015","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.cardfail.2016.04.008","article-title":"Models of Heart failure based on the cardiotoxicity of anticancer drugs","volume":"22","author":"Mercurio","year":"2016","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.lfs.2020.117843_bb0020","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2020.117843_bb0025","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.med.57.121304.131240","article-title":"Cardiotoxicity induced by chemotherapy and antibody therapy","volume":"57","author":"Yeh","year":"2006","journal-title":"Ann. Rev. Med."},{"key":"10.1016\/j.lfs.2020.117843_bb0030","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1016\/j.jacc.2017.09.1096","article-title":"Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management\u2014part 1","volume":"70","author":"Chang","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.lfs.2020.117843_bb0035","first-page":"14","article-title":"Cardiotoxicity after cancer treatment: a process map of the patient treatment journey","volume":"5","author":"Clark","year":"2019","journal-title":"Cardiooncology"},{"key":"10.1016\/j.lfs.2020.117843_bb0040","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/14737140.2019.1596804","article-title":"Oncologic therapies associated with cardiac toxicities: how to minimize the risks","volume":"19","author":"Cardinale","year":"2019","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.lfs.2020.117843_bb0045","article-title":"Right ventricular involvement in cancer therapy-related cardiotoxicity: the emerging role of strain echocardiography","author":"Keramida","year":"2020","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.lfs.2020.117843_bb0050","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11897-020-00453-3","article-title":"Personalized approach to cancer treatment-related cardiomyopathy","volume":"17","author":"Slivnick","year":"2020","journal-title":"Curr. Heart Fail Rep."},{"issue":"38","key":"10.1016\/j.lfs.2020.117843_bb0055","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1200\/EDBK_100015","article-title":"Predicting and preventing anthracycline-related cardiotoxicity","author":"Armenian","year":"2018","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"10.1016\/j.lfs.2020.117843_bb0060","first-page":"900","article-title":"Shared risk factors for cardiovascular disease and cancer: implications for preventive health and clinical care in oncology patients","volume":"32","author":"Johnson","year":"2016","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.lfs.2020.117843_bb0065","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ejca.2013.11.013","article-title":"Effect of obesity on disease-free and overall survival in node-positive breast cancer patients in a large French population: a pooled analysis of two randomised trials","volume":"50","author":"Ladoire","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lfs.2020.117843_bb0070","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10549-009-0512-0","article-title":"The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial","volume":"119","author":"de Azambuja","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.lfs.2020.117843_bb0075","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0140-6736(08)60269-X","article-title":"Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies","volume":"371","author":"Renehan","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2020.117843_bb0080","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cgh.2005.12.007","article-title":"The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence","volume":"4","author":"El-Serag","year":"2006","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.lfs.2020.117843_bb0085","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1001\/jama.1995.03520440059037","article-title":"Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis","volume":"273","author":"Everhart","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.lfs.2020.117843_bb0090","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1634\/theoncologist.2009-0285","article-title":"Obesity and cancer","volume":"15","author":"Wolin","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.lfs.2020.117843_bb0095","first-page":"88","article-title":"Global patterns in excess body weight and the associated cancer burden","volume":"69","author":"Sung","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lfs.2020.117843_bb0100","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/S2213-8587(18)30150-5","article-title":"Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment","volume":"6","author":"Pearson-Stuttard","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.lfs.2020.117843_bb0105","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/annonc\/mdn728","article-title":"Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk","volume":"20","author":"Barrett-Lee","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lfs.2020.117843_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002989","article-title":"Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study","volume":"16","author":"Kabor\u00e9","year":"2019","journal-title":"PLoS Med."},{"key":"10.1016\/j.lfs.2020.117843_bb0115","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","article-title":"Anthracycline chemotherapy and cardiotoxicity","volume":"31","author":"McGowan","year":"2017","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.lfs.2020.117843_bb0120","doi-asserted-by":"crossref","DOI":"10.1177\/1179546819866445","article-title":"Cancer therapy-related cardiac dysfunction: an overview for the clinician","volume":"13","author":"Perez","year":"2019","journal-title":"Clin. Med. Insights Cardiol."},{"key":"10.1016\/j.lfs.2020.117843_bb0125","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1136\/heartjnl-2017-312103","article-title":"Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention","volume":"104","author":"Henriksen","year":"2018","journal-title":"Heart"},{"key":"10.1016\/j.lfs.2020.117843_bb0130","article-title":"Anthracycline versus nonanthracycline adjuvant therapy for early breast cancer. A systematic review and meta-analysis","volume":"97","author":"Ding","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.lfs.2020.117843_bb0135","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/157340311799960645","article-title":"Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment","volume":"7","author":"Volkova","year":"2011","journal-title":"Curr. Cardiol. Rev."},{"key":"10.1016\/j.lfs.2020.117843_bb0140","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.lfs.2020.117843_bb0145","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1161\/CIRCULATIONAHA.115.016704","article-title":"Anthracycline cardiotoxicity: a new paradigm for an old classic","volume":"131","author":"Groarke","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.lfs.2020.117843_bb0150","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10741-016-9564-5","article-title":"Current views on anthracycline cardiotoxicity","volume":"21","author":"Mele","year":"2016","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.lfs.2020.117843_bb0155","first-page":"13","article-title":"Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers","volume":"1","author":"Mohan","year":"2018","journal-title":"Antib. Ther."},{"key":"10.1016\/j.lfs.2020.117843_bb0160","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2020.117843_bb0165","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","article-title":"11 years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin adjuvant (HERA) trial","volume":"389","author":"Cameron","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2020.117843_bb0170","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1111\/bph.13643","article-title":"Trastuzumab cardiotoxicity: from clinical trials to experimental studies","volume":"174","author":"Nemeth","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2020.117843_bb0175","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/jnci\/djs317","article-title":"Pharmacovigilance study team. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study","volume":"104","author":"Bowles","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.lfs.2020.117843_bb0180","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0025-6196(11)60840-9","article-title":"Trastuzumab-induced cardiotoxicity: heart failure at the crossroads","volume":"83","author":"Sengupta","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.lfs.2020.117843_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079543","article-title":"Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice","volume":"8","author":"ElZarrad","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2020.117843_bb0190","article-title":"The temporal risk of heart failure associated with adjuvant trastuzumab in breast cancer patients: a population study","volume":"16","author":"Goldhar","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.lfs.2020.117843_bb0195","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1182\/blood-2010-06-291328","article-title":"Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation","volume":"117","author":"Galper","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2020.117843_bb0200","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1161\/CIRCULATIONAHA.116.025434","article-title":"Risk of Heart failure with preserved ejection fraction in older women after contemporary radiotherapy for breast cancer","volume":"135","author":"Saiki","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.lfs.2020.117843_bb0205","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1016\/j.jacc.2013.01.090","article-title":"Cardiac complications of thoracic irradiation","volume":"61","author":"Jaworski","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.lfs.2020.117843_bb0210","first-page":"3913","article-title":"Effectiveness of exercise-based rehabilitation on functional capacity and quality of life in head and neck cancer patients receiving chemo-radiotherapy","volume":"27","author":"Samuel","year":"2019","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.lfs.2020.117843_bb0215","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.amjcard.2019.12.019","article-title":"Determinants of cardiorespiratory fitness following thoracic radiotherapy in lung or breast cancer survivors","volume":"125","author":"Canada","year":"2020","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.lfs.2020.117843_bb0220","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1517\/14656566.2012.737780","article-title":"Vemurafenib for the treatment of melanoma","volume":"13","author":"Jordan","year":"2012","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.lfs.2020.117843_bb0225","article-title":"Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer","volume":"20","author":"Gibson","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.lfs.2020.117843_bb0230","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40425-016-0117-1","article-title":"Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study","volume":"4","author":"Koelzer","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.lfs.2020.117843_bb0235","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/heartjnl-2011-301515","article-title":"Characterising the myocardial interstitial space: the clinical relevance of non-invasive imaging","volume":"98","author":"White","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.lfs.2020.117843_bb0240","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1038\/s41598-017-02627-x","article-title":"Early detection and serial monitoring of anthracycline-induced cardiotoxicity using T1-mapping cardiac magnetic resonance imaging: an animal study","volume":"7","author":"Hong","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2020.117843_bb0245","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1470-2045(05)01719-5","article-title":"Use of endomyocardial biopsy to assess anthracycline-induced cardiotoxicity","volume":"6","author":"Jones","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lfs.2020.117843_bb0250","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1634\/theoncologist.2012-0239","article-title":"Association of anthracycline-related cardiac histological lesions with NADPH oxidase functional polymorphisms","volume":"18","author":"Cascales","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.lfs.2020.117843_bb0255","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2217\/fca.15.16","article-title":"Current and emerging modalities for detection of cardiotoxicity in cardio-oncology","volume":"11","author":"Khouri","year":"2015","journal-title":"Futur. Cardiol."},{"key":"10.1016\/j.lfs.2020.117843_bb0260","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1093\/eurheartj\/ehl013","article-title":"Tissue Doppler imaging predicts left ventricular dysfunction and mortality in a murine model of cardiac injury","volume":"27","author":"Neilan","year":"2006","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.lfs.2020.117843_bb0265","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.echo.2010.02.015","article-title":"Assessment of myocardial mechanics using speckle tracking echocardiography: fundamentals and clinical applications","volume":"23","author":"Geyer","year":"2010","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"10.1016\/j.lfs.2020.117843_bb0270","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/ehjci\/jes217","article-title":"Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study","volume":"14","author":"Mavinkurve-Groothuis","year":"2013","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"10.1016\/j.lfs.2020.117843_bb0275","first-page":"279","article-title":"Analysis in the assessment of a mouse model of cardiotoxicity due to chemotherapy: sample for preclinical research","volume":"30","author":"Rea","year":"2016","journal-title":"In Vivo"},{"key":"10.1016\/j.lfs.2020.117843_bb0280","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11912-016-0533-x","article-title":"Cardiac MRI: a translational imaging tool for characterizing anthracycline-induced myocardial remodeling","volume":"18","author":"Nguyen","year":"2016","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.lfs.2020.117843_bb0285","first-page":"4","article-title":"Use of integrated imaging and serum biomarker profiles to identify subclinical dysfunction in pediatric cancer patients treated with anthracyclines","volume":"4","author":"Toro-Salazar","year":"2018","journal-title":"Cardiooncology"},{"key":"10.1016\/j.lfs.2020.117843_bb0290","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.115.003584","article-title":"Characterization of the changes in cardiac structure and function in mice treated with anthracyclines using serial cardiac magnetic resonance imaging","volume":"9","author":"Farhad","year":"2016","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"10.1016\/j.lfs.2020.117843_bb0295","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jacc.2018.11.046","article-title":"Serial magnetic resonance imaging to identify early stages of anthracycline-induced cardiotoxicity","volume":"73","author":"Gal\u00e1n-Arriola","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.lfs.2020.117843_bb0300","first-page":"487","article-title":"Emerging cardiac imaging modalities for the early detection of cardiotoxicity due to anticancer therapies","volume":"70","author":"L\u00f3pez\u2013Fern\u00e1ndez","year":"2017","journal-title":"Rev. Esp. Cardiol."},{"key":"10.1016\/j.lfs.2020.117843_bb0305","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/ehjci\/jex010","article-title":"Demonstration of infective endocarditis by cardiac CT and transoesophageal echocardiography: comparison with intraoperative findings","volume":"19","author":"Koo","year":"2018","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"10.1016\/j.lfs.2020.117843_bb0310","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013755","article-title":"Multimodality cardiac imaging in the era of emerging cancer therapies","volume":"9","author":"Biersmith","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.lfs.2020.117843_bb0315","first-page":"1283","article-title":"Metaiodobenzylguanidine: evaluation of its potential as a tracer for monitoring doxorubicin cardiomyopathy","volume":"34","author":"Wakasugi","year":"1993","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.lfs.2020.117843_bb0320","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/263950","article-title":"Multimodality imaging in cardiooncology","volume":"2015","author":"Pizzino","year":"2015","journal-title":"J. Oncol."},{"key":"10.1016\/j.lfs.2020.117843_bb0325","first-page":"2044","article-title":"Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity","volume":"36","author":"Carri\u00f3 I","year":"1995","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.lfs.2020.117843_bb0330","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pharmthera.2018.04.009","article-title":"Anticancer drug-induced cardiac rhythm disorders: current knowledge and basic underlying mechanisms","volume":"189","author":"Alexandre","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.lfs.2020.117843_bb0335","article-title":"Electrophysiology translational considerations in cardio-oncology: QT and beyond","author":"Alomar","year":"2019","journal-title":"J. Cardiovasc. Trans. Res."},{"key":"10.1016\/j.lfs.2020.117843_bb0340","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.117.005443","article-title":"Cancer treatment-induced arrhythmias: focus on chemotherapy and targeted therapies","volume":"10","author":"Buza","year":"2017","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"10.1016\/j.lfs.2020.117843_bb0345","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010101","article-title":"Incidence of cancer treatment-induced arrhythmia associated with novel targeted chemotherapeutic agents","volume":"7","author":"Nickel","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.lfs.2020.117843_bb0350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196763","article-title":"Effects of anthracycline, cyclophosphamide and taxane chemotherapy on QTc measurements in patients with breast cancer","volume":"13","author":"Veronese","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2020.117843_bb0355","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/toxsci\/kfp092","article-title":"Continuous electrocardiogram reveals differences in the short-term cardiotoxic response of Wistar-Kyoto and spontaneously hypertensive rats to doxorubicin","volume":"110","author":"Hazari","year":"2009","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.lfs.2020.117843_bb0360","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s12012-012-9172-0","article-title":"Doxorubicin-induced changes of ventricular repolarization heterogeneity: results of a chronic rat study","volume":"12","author":"Kharin","year":"2012","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.lfs.2020.117843_bb0365","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1200\/JCO.1999.17.7.2237","article-title":"Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin","volume":"17","author":"Herman","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2020.117843_bb0370","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","article-title":"Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy","volume":"109","author":"Cardinale","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.lfs.2020.117843_bb0375","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.2459\/JCM.0000000000000381","article-title":"A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian society of cardiology","volume":"17","author":"Spallarossa","year":"2016","journal-title":"J. Cardiovasc. Med."},{"key":"10.1016\/j.lfs.2020.117843_bb0380","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","article-title":"Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab","volume":"5","author":"Sawaya","year":"2012","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"10.1016\/j.lfs.2020.117843_bb0385","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0009-8981(03)00013-5","article-title":"Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings","volume":"329","author":"Bertinchant","year":"2003","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.lfs.2020.117843_bb0390","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.tox.2007.05.016","article-title":"In vitro and in vivo examination of cardiac troponins as biochemical markers of drug-induced cardiotoxicity","volume":"237","author":"Adamcov\u00e1","year":"2007","journal-title":"Toxicology"},{"key":"10.1016\/j.lfs.2020.117843_bb0395","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.amjcard.2011.01.006","article-title":"Early detection and prediction of cardiotoxicity in chemotherapy-treated patients","volume":"107","author":"Sawaya","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.lfs.2020.117843_bb0400","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab","volume":"63","author":"Ky","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.lfs.2020.117843_bb0405","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/bjc.2011.439","article-title":"Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients","volume":"105","author":"Romano","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lfs.2020.117843_bb0410","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014708","article-title":"Changes in cardiovascular biomarkers with breast cancer therapy and associations with cardiac dysfunction","volume":"9","author":"Demissei","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.lfs.2020.117843_bb0415","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/ejhf.1631","article-title":"Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis","volume":"22","author":"Michel","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.lfs.2020.117843_bb0420","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/14737159.2017.1283219","article-title":"Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy","volume":"17","author":"Cardinale","year":"2017","journal-title":"Expert. Rev. Mol. Diagn."},{"key":"10.1016\/j.lfs.2020.117843_bb0425","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.hfc.2016.12.009","article-title":"Alternative biomarkers for combined biology","volume":"13","author":"Kim","year":"2017","journal-title":"Heart Fail. Clin."},{"key":"10.1016\/j.lfs.2020.117843_bb0430","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11936-018-0641-z","article-title":"Role of biomarkers in prediction of cardiotoxicity during cancer treatment","volume":"20","author":"Tan","year":"2018","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"10.1016\/j.lfs.2020.117843_bb0435","first-page":"E33","article-title":"Myeloperoxidase as an active disease biomarker: recent biochemical and pathological perspectives","volume":"6","author":"Khan","year":"2018","journal-title":"Med. Sci."},{"key":"10.1016\/j.lfs.2020.117843_bb0440","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1373\/clinchem.2015.241232","article-title":"Longitudinal changes in multiple biomarkers are associated with cardiotoxicity in breast cancer patients treated with doxorubicin, Taxanes, and Trastuzumab","volume":"61","author":"Putt","year":"2015","journal-title":"Clin. Chem."},{"key":"10.1016\/j.lfs.2020.117843_bb0445","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10741-017-9653-0","article-title":"Role of microRNAs in doxorubicin-induced cardiotoxicity: an overview of preclinical models and cancer patients","volume":"23","author":"Ruggeri","year":"2018","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.lfs.2020.117843_bb0450","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/cvr\/cvq148","article-title":"Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway","volume":"87","author":"Horie","year":"2010","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.lfs.2020.117843_bb0455","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040395","article-title":"Perturbation of microRNAs in rat heart during chronic doxorubicin treatment","volume":"7","author":"Vacchi-Suzzi","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2020.117843_bb0460","doi-asserted-by":"crossref","first-page":"62312","DOI":"10.18632\/oncotarget.11468","article-title":"MicroRNA-34a regulates doxorubicin-induced cardiotoxicity in rat","volume":"7","author":"Piegari","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.lfs.2020.117843_bb0465","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.redox.2017.12.013","article-title":"MicroRNA-140-5p aggravates doxorubicin-induced cardiotoxicity by promoting myocardial oxidative stress via targeting Nrf2 and Sirt2","volume":"15","author":"Zhao","year":"2018","journal-title":"Redox Biol."},{"key":"10.1016\/j.lfs.2020.117843_bb0470","doi-asserted-by":"crossref","first-page":"6994","DOI":"10.18632\/oncotarget.14355","article-title":"Circulating miR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients","volume":"8","author":"Rigaud","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.lfs.2020.117843_bb0475","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.3390\/jcm9051418","article-title":"Circulating microRNAs as potential predictors of Anthracycline-induced troponin elevation in breast cancer patients: diverging effects of Doxorubicin and Epirubicin","volume":"9","author":"Gioffr\u00e9","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.lfs.2020.117843_bb0480","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40169-017-0148-3","article-title":"Anthracycline induced cardiotoxicity: biomarkers and \"Omics\" technology in the era of patient specific care","volume":"6","author":"Moazeni","year":"2017","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.lfs.2020.117843_bb0485","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1200\/JCO.2009.27.3011","article-title":"Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis","volume":"29","author":"Peairs","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2020.117843_bb0490","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1093\/annonc\/mdu042","article-title":"Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies","volume":"25","author":"Chan","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lfs.2020.117843_bb0495","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-019-0128-4","article-title":"Obesity and survival among a cohort of breast cancer patients is partially mediated by tumor characteristics","volume":"5","author":"Blair","year":"2019","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.lfs.2020.117843_bb0500","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11912-019-0787-1","article-title":"The impact of obesity on breast cancer diagnosis and treatment","volume":"21","author":"Lee","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.lfs.2020.117843_bb0505","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2337\/dc17-2012","article-title":"The impact of diabetes on breast cancer treatments and outcomes: a population-based study","volume":"41","author":"Lega","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lfs.2020.117843_bb0510","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005602","article-title":"Diabetes mellitus and prognosis in women with breast cancer: a systematic review and meta-analysis","volume":"95","author":"Zhao","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.lfs.2020.117843_bb0515","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1200\/JCO.2008.17.5935","article-title":"Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer","volume":"27","author":"Srokowski","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2020.117843_bb0520","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13058-018-1087-7","article-title":"Impact of obesity on breast cancer recurrence and minimal residual disease","volume":"21","author":"Ecker","year":"2019","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.lfs.2020.117843_bb0525","article-title":"Body mass index predicts cardiac toxicity following anthracycline-based chemotherapy","volume":"128","author":"Serrano","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.lfs.2020.117843_bb0530","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1200\/JCO.2016.67.4846","article-title":"Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer: A systematic review and meta-analysis","volume":"34","author":"Guenancia","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2020.117843_bb0535","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/1078155214567162","article-title":"Risk factors for developing cardiotoxicity of trastuzumab in breast cancer patients: an observational single-centre study","volume":"22","author":"Gunaldi","year":"2016","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.lfs.2020.117843_bb0540","doi-asserted-by":"crossref","first-page":"79289","DOI":"10.18632\/oncotarget.17808","article-title":"Association between obesity and trastuzumab-related cardiac toxicity in elderly patients with breast cancer","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.lfs.2020.117843_bb0545","doi-asserted-by":"crossref","first-page":"e314","DOI":"10.3747\/co.26.4823","article-title":"Effect of obesity, dyslipidemia, and diabetes on trastuzumab-related cardiotoxicity in breast cancer","volume":"26","author":"Kosalka","year":"2019","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.lfs.2020.117843_bb0550","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/COC.0b013e3181e1d0c0","article-title":"Hyperglycemia during chemotherapy for hematologic and solid tumors is correlated with increased toxicity","volume":"34","author":"Brunello","year":"2011","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2020.117843_bb0555","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.critrevonc.2017.03.007","article-title":"Impact of hyperglycemia on the efficacy of chemotherapy-A systematic review of preclinical studies","volume":"113","author":"Gerards","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.lfs.2020.117843_bb0560","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40137-018-0204-y","article-title":"Obesity, metabolic syndrome, and breast cancer: from prevention to intervention","volume":"6","author":"Li","year":"2018","journal-title":"Curr. Surg. Rep."},{"issue":"2018","key":"10.1016\/j.lfs.2020.117843_bb0565","article-title":"Using zebrafish for investigating the molecular mechanisms of drug-induced cardiotoxicity","author":"Zakaria","year":"2018","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.lfs.2020.117843_bb0570","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10741-015-9497-4","article-title":"Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a position paper of the Italian working group on drug cardiotoxicity and cardioprotection","volume":"20","author":"Madonna","year":"2015","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.lfs.2020.117843_bb0575","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.taap.2008.05.006","article-title":"High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity","volume":"231","author":"Mitra","year":"2008","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.lfs.2020.117843_bb0580","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s00280-013-2154-5","article-title":"Switching to a low-fat diet attenuates the intensified doxorubicin cardiotoxicity associated with high-fat feeding","volume":"71","author":"Hydock","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.lfs.2020.117843_bb0585","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00280-016-2995-9","article-title":"Overweight in mice, induced by perinatal programming, exacerbates doxorubicin and trastuzumab cardiotoxicity","volume":"77","author":"Guenancia","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.lfs.2020.117843_bb0590","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/aps.2011.203","article-title":"Laboratory animals as surrogate models of human obesity","volume":"33","author":"Nilsson","year":"2012","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.lfs.2020.117843_bb0595","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3389\/fphys.2016.00334","article-title":"S100A8 and S100A9 are associated with doxorubicin-induced cardiotoxicity in the heart of diabetic mice","volume":"7","author":"Pei","year":"2016","journal-title":"Front. Physiol."},{"key":"10.1016\/j.lfs.2020.117843_bb0600","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1006\/phrs.1999.0568","article-title":"Effect of streptozotocin-induced hyperglycaemia on intravenous pharmacokinetics and acute cardiotoxicity of doxorubicin in rats","volume":"41","author":"Al-Shabanah","year":"2000","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.lfs.2020.117843_bb0605","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/cvr\/cvx246","article-title":"Anthracycline cardiotoxicity: the importance of horizontally integrating pre-clinical and clinical research","volume":"114","author":"Lipshultz","year":"2018","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.lfs.2020.117843_bb0610","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF00434396","article-title":"Doxorubicin pharmacokinetics after intravenous and intraperitoneal administration in the nude mouse","volume":"5","author":"Johansen","year":"1981","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.lfs.2020.117843_bb0615","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1200\/JCO.2007.14.9401","article-title":"Anthracycline cardiotoxicity: from bench to bedside","volume":"26","author":"Gianni","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2020.117843_bb0620","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13287-015-0142-x","article-title":"Comparison of adipose tissue- and bone marrow-derived mesenchymal stem cells for alleviating doxorubicin-induced cardiac dysfunction in diabetic rats","volume":"6","author":"Ammar","year":"2015","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.lfs.2020.117843_bb0625","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1515\/hmbci-2014-0001","article-title":"Roles of oxidative stress, adiponectin, and nuclear hormone receptors in obesity-associated insulin resistance and cardiovascular risk","volume":"19","author":"Matsuda","year":"2014","journal-title":"Horm. Mol. Biol. Clin. Investig."},{"key":"10.1016\/j.lfs.2020.117843_bb0630","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1177\/0300060517706578","article-title":"Cardiovascular risk of adipokines: a review","volume":"46","author":"Dutheil","year":"2018","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.lfs.2020.117843_bb0635","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/j.biochi.2012.06.030","article-title":"Adiponectin: anti-inflammatory and cardioprotective effects","volume":"94","author":"Villarreal-Molina","year":"2012","journal-title":"Biochimie"},{"issue":"2014","key":"10.1016\/j.lfs.2020.117843_bb0640","article-title":"New insight into adiponectin role in obesity and obesity-related diseases","author":"Nigro","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.lfs.2020.117843_bb0645","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nm1295","article-title":"Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms","volume":"11","author":"Shibata","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.lfs.2020.117843_bb0650","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1038\/nm1137","article-title":"Adiponectin-mediated modulation of hypertrophic signals in the heart","volume":"10","author":"Shibata","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.lfs.2020.117843_bb0655","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/oby.2008.545","article-title":"Adiponectin improves cardiomyocyte contractile function in db\/db diabetic obese mice","volume":"17","author":"Dong","year":"2009","journal-title":"Obesity"},{"key":"10.1016\/j.lfs.2020.117843_bb0660","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cvr\/cvq335","article-title":"Adiponectin protects against doxorubicin-induced cardiomyopathy by anti-apoptotic effects through AMPK up-regulation","volume":"89","author":"Konishi","year":"2011","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.lfs.2020.117843_bb0665","doi-asserted-by":"crossref","first-page":"32790","DOI":"10.1074\/jbc.M111.245985","article-title":"Adiponectin ameliorates doxorubicin-induced cardiotoxicity through Akt protein-dependent mechanism","volume":"286","author":"Maruyama","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2020.117843_bb0670","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2174\/1570161112999140217095038","article-title":"Omentin: linking metabolic syndrome and cardiovascular disease","volume":"12","author":"Zhou","year":"2014","journal-title":"Curr. Vasc. Pharmacol."},{"key":"10.1016\/j.lfs.2020.117843_bb0675","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.2337\/db06-1506","article-title":"Omentin plasma levels and gene expression are decreased in obesity","volume":"56","author":"de Souza Batista","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.lfs.2020.117843_bb0680","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/6762825","article-title":"Circulating Omentin-1 levels are decreased in dilated cardiomyopathy patients with overt heart failure","volume":"2016","author":"Huang","year":"2016","journal-title":"Dis. Markers"},{"key":"10.1016\/j.lfs.2020.117843_bb0685","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bbrc.2015.01.032","article-title":"Adipocytokine, omentin inhibits doxorubicin-induced H9c2 cardiomyoblasts apoptosis through the inhibition of mitochondrial reactive oxygen species","volume":"457","author":"Kazama","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.lfs.2020.117843_bb0690","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212782","article-title":"Omentin protects H9c2 cells against docetaxel cardiotoxicity","volume":"14","author":"Lage","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2020.117843_bb0695","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35053000","article-title":"The hormone resistin links obesity to diabetes","volume":"409","author":"Steppan","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2020.117843_bb0700","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1007\/s00125-006-0173-z","article-title":"Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin","volume":"49","author":"Curat","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.lfs.2020.117843_bb0705","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1093\/eurjhf\/hfs111","article-title":"High leptin and resistin expression in chronic heart failure: adverse outcome in patients with dilated and inflammatory cardiomyopathy","volume":"14","author":"Bobbert","year":"2012","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.lfs.2020.117843_bb0710","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.orcp.2015.08.017","article-title":"Evaluation of diagnostic and predictive value of serum adipokines: leptin, resistin and visfatin in postmenopausal breast cancer","volume":"10","author":"Assiri","year":"2016","journal-title":"Obes. Res. Clin. Pract."},{"key":"10.1016\/j.lfs.2020.117843_bb0715","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1210\/en.2013-1399","article-title":"Human resistin in chemotherapy-induced heart failure in humanized male mice and in women treated for breast cancer","volume":"154","author":"Schwartz","year":"2013","journal-title":"Endocrinology"},{"key":"10.1016\/j.lfs.2020.117843_bb0720","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/7582730","article-title":"Chemotherapeutic drugs and mitochondrial dysfunction: focus on doxorubicin, trastuzumab, and sunitinib","volume":"2018","author":"Gorini","year":"2018","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.lfs.2020.117843_bb0725","series-title":"Mitochondrial Diseases","article-title":"Mitochondrial dysfunction associated with doxorubicin","author":"Guven","year":"2018"},{"key":"10.1016\/j.lfs.2020.117843_bb0730","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2174\/1568026619666190401112948","article-title":"Topoisomerase inhibitors and targeted delivery in cancer therapy","volume":"19","author":"You","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.lfs.2020.117843_bb0735","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3389\/fcvm.2020.00035","article-title":"Mechanisms of anthracycline-induced cardiotoxicity: is mitochondrial dysfunction the answer?","volume":"7","author":"Murabito","year":"2020","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.lfs.2020.117843_bb0740","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.lfs.2020.117843_bb0745","doi-asserted-by":"crossref","first-page":"H1453","DOI":"10.1152\/ajpheart.00554.2015","article-title":"Drug-induced mitochondrial dysfunction and cardiotoxicity","volume":"309","author":"Varga","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.lfs.2020.117843_bb0750","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002555","article-title":"Mitochondrial reactive oxygen species mediate cardiac structural, functional, and mitochondrial consequences of diet-induced metabolic heart disease","volume":"5","author":"Sverdlov","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.lfs.2020.117843_bb0755","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.bbadis.2016.11.010","article-title":"Mitochondrial dysfunction and oxidative stress in metabolic disorders - a step towards mitochondria based therapeutic strategies","volume":"1863","author":"Bhatti","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.lfs.2020.117843_bb0760","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/795602","article-title":"Chemotherapy-induced cardiotoxicity: overview of the roles of oxidative stress","volume":"2015","author":"Angsutararux","year":"2015","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.lfs.2020.117843_bb0765","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1016\/j.jacc.2007.02.060","article-title":"Potentiation of doxorubicin cardiotoxicity by iron loading in a rodent model","volume":"49","author":"Panjrath","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.lfs.2020.117843_bb0770","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1172\/JCI72931","article-title":"Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation","volume":"124","author":"Ichikawa","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"2015","key":"10.1016\/j.lfs.2020.117843_bb0775","article-title":"Iron-induced damage in cardiomyopathy: oxidative-dependent and independent mechanisms","author":"Gammella","year":"2015","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.lfs.2020.117843_bb0780","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1734-1140(09)70018-0","article-title":"Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron","volume":"61","author":"Sim\u016fnek","year":"2009","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.lfs.2020.117843_bb0785","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1089\/ars.2010.3739","article-title":"Oxidative stress as pathogenesis of cardiovascular risk associated with metabolic syndrome","volume":"15","author":"Otani","year":"2011","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.lfs.2020.117843_bb0790","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.bbagen.2013.11.007","article-title":"Mitochondrial dysfunction and complications associated with diabetes","volume":"1840","author":"Blake","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.lfs.2020.117843_bb0795","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/sj.ijo.0801536","article-title":"Mechanism for obesity-induced increase in myocardial lipid peroxidation","volume":"25","author":"Vincent","year":"2001","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"10.1016\/j.lfs.2020.117843_bb0800","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1758-5996-3-17","article-title":"Biochemical study of oxidative stress markers in the liver, kidney and heart of high fat diet induced obesity in rats","volume":"3","author":"Noeman","year":"2011","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.lfs.2020.117843_bb0805","doi-asserted-by":"crossref","first-page":"H2181","DOI":"10.1152\/ajpheart.00554.2011","article-title":"Oxidative stress and heart failure","volume":"301","author":"Tsutsui","year":"2011","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.lfs.2020.117843_bb0810","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1124\/mol.114.093849","article-title":"Adverse effects of doxorubicin and its metabolic product on cardiac RyR2 and SERCA2A","volume":"86","author":"Hanna","year":"2014","journal-title":"Mol. Pharmacol."},{"issue":"2012","key":"10.1016\/j.lfs.2020.117843_bb0815","article-title":"Mitochondria death\/survival signaling pathways in cardiotoxicity induced by anthracyclines and anticancer-targeted therapies","author":"Montaigne","year":"2012","journal-title":"Biochem. Res. Int."},{"key":"10.1016\/j.lfs.2020.117843_bb0820","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/cvr\/cvm047","article-title":"Bidirectional regulation of Ca2+ sparks by mitochondria-derived reactive oxygen species in cardiac myocytes","volume":"77","author":"Yan","year":"2008","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.lfs.2020.117843_bb0825","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.redox.2015.08.010","article-title":"Calcium and ROS: a mutual interplay","volume":"6","author":"G\u00f6rlach","year":"2015","journal-title":"Redox Biol."},{"key":"10.1016\/j.lfs.2020.117843_bb0830","doi-asserted-by":"crossref","first-page":"E1617","DOI":"10.3390\/cells8121617","article-title":"Imbalance of ER and mitochondria interactions: prelude to cardiac ageing and disease?","volume":"8","author":"Li","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.lfs.2020.117843_bb0835","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2147\/DMSO.S30005","article-title":"Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?","volume":"5","author":"Dincer","year":"2012","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"10.1016\/j.lfs.2020.117843_bb0840","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ceca.2014.09.005","article-title":"Regulation of SERCA pumps expression in diabetes","volume":"56","author":"Zarain-Herzberg","year":"2014","journal-title":"Cell Calcium"},{"key":"10.1016\/j.lfs.2020.117843_bb0845","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.3389\/fphys.2018.01517","article-title":"Proarrhythmic remodeling of calcium homeostasis in cardiac disease; implications for diabetes and obesity","volume":"9","author":"Hamilton","year":"2018","journal-title":"Front. Physiol."},{"key":"10.1016\/j.lfs.2020.117843_bb0850","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1006\/abbi.1998.1011","article-title":"Manganese superoxide dismutase protects mitochondrial complex I against adriamycin-induced cardiomyopathy in transgenic mice","volume":"362","author":"Yen","year":"1999","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.lfs.2020.117843_bb0855","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.freeradbiomed.2006.02.024","article-title":"Attenuation of doxorubicin-induced contractile and mitochondrial dysfunction in mouse heart by cellular glutathione peroxidase","volume":"41","author":"Xiong","year":"2006","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.lfs.2020.117843_bb0860","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074675","article-title":"Creatine kinase-overexpression improves myocardial energetics, contractile dysfunction and survival in murine doxorubicin cardiotoxicity","volume":"8","author":"Gupta","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2020.117843_bb0865","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/9340654","article-title":"Cell death and heart failure in obesity: role of uncoupling proteins","volume":"2016","author":"Ruiz-Ram\u00edrez","year":"2016","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.lfs.2020.117843_bb0870","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.2337\/db07-0481","article-title":"Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins","volume":"56","author":"Boudina","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.lfs.2020.117843_bb0875","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fphys.2015.00036","article-title":"Mitochondrial uncoupling proteins and energy metabolism","volume":"6","author":"Busiello","year":"2015","journal-title":"Front. Physiol."},{"key":"10.1016\/j.lfs.2020.117843_bb0880","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.2337\/diabetes.54.12.3496","article-title":"Plasma free fatty acids and peroxisome proliferator-activated receptor alpha in the control of myocardial uncoupling protein levels","volume":"54","author":"Murray","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.lfs.2020.117843_bb0885","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00395-011-0156-1","article-title":"A high fat diet increases mitochondrial fatty acid oxidation and uncoupling to decrease efficiency in rat heart","volume":"106","author":"Cole","year":"2011","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.lfs.2020.117843_bb0890","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1038\/emm.2016.81","article-title":"Regulation and function of AMPK in physiology and diseases","volume":"48","author":"Jeon","year":"2016","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.lfs.2020.117843_bb0895","doi-asserted-by":"crossref","first-page":"5207","DOI":"10.2174\/0929867325666180406120051","article-title":"Targeting AMPK in diabetes and diabetic complications: energy homeostasis, autophagy and mitochondrial health","volume":"26","author":"Madhavi","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.lfs.2020.117843_bb0900","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.2337\/db08-1361","article-title":"Nutrient stress activates inflammation and reduces glucose metabolism by suppressing AMP-activated protein kinase in the heart","volume":"58","author":"Ko","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.lfs.2020.117843_bb0905","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s13105-012-0199-2","article-title":"A high-fat diet decreases AMPK activity in multiple tissues in the absence of hyperglycemia or systemic inflammation in rats","volume":"69","author":"Lindholm","year":"2013","journal-title":"J. Physiol. Biochem."},{"key":"10.1016\/j.lfs.2020.117843_bb0910","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.bbadis.2016.07.001","article-title":"The role of AMPK in cardiomyocyte health and survival","volume":"1862","author":"Bairwa","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.lfs.2020.117843_bb0915","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.yjmcc.2010.12.007","article-title":"Deficiency in AMP-activated protein kinase exaggerates high fat diet-induced cardiac hypertrophy and contractile dysfunction","volume":"50","author":"Turdi","year":"2011","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.lfs.2020.117843_bb0920","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10557-020-06941-x","article-title":"The role of AMPK activation for cardioprotection in doxorubicin-induced cardiotoxicity","volume":"34","author":"Timm","year":"2020","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.lfs.2020.117843_bb0925","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cbi.2015.12.010","article-title":"Doxorubicin toxicity changes myocardial energy metabolism in rats","volume":"244","author":"Wu","year":"2016","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.lfs.2020.117843_bb0930","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.3892\/mmr.2015.4665","article-title":"Resveratrol protects cardiomyocytes from doxorubicin-induced apoptosis through the AMPK\/P53 pathway","volume":"13","author":"Liu","year":"2016","journal-title":"Mol. Med. Rep."},{"issue":"2008","key":"10.1016\/j.lfs.2020.117843_bb0935","article-title":"The PPARalpha-PGC-1alpha axis controls cardiac energy metabolism in healthy and diseased myocardium","author":"Duncan","year":"2008","journal-title":"PPAR Res."},{"key":"10.1016\/j.lfs.2020.117843_bb0940","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3389\/fcvm.2020.00002","article-title":"Multiple levels of PGC-1\u03b1 dysregulation in heart failure","volume":"7","author":"Oka","year":"2020","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.lfs.2020.117843_bb0945","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2016.05.021","article-title":"Interleukin 6 modulates PPAR\u03b1 and PGC-1\u03b1 and is involved in high-fat diet induced cardiac lipotoxicity in mouse","volume":"219","author":"Bonda","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.lfs.2020.117843_bb0950","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.yjmcc.2014.12.001","article-title":"Mitochondrial remodeling in mice with cardiomyocyte-specific lipid overload","volume":"79","author":"Elezaby","year":"2015","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.lfs.2020.117843_bb0955","first-page":"2435","article-title":"Effects of PPAR\u03b1\/PGC-1\u03b1 on the myocardial energy metabolism during heart failure in the doxorubicin induced dilated cardiomyopathy in mice","volume":"7","author":"Yang","year":"2014","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.lfs.2020.117843_bb0960","first-page":"12216","article-title":"Effects of PPAR\u03b1\/PGC-1\u03b1 on the energy metabolism remodeling and apoptosis in the doxorubicin induced mice cardiomyocytes in vitro","volume":"8","author":"Yang","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.lfs.2020.117843_bb0965","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/nm1116","article-title":"Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy","volume":"10","author":"Cheng","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.lfs.2020.117843_bb0970","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1172\/JCI27955","article-title":"PPAR delta: a dagger in the heart of the metabolic syndrome","volume":"116","author":"Barish","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.lfs.2020.117843_bb0975","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/cvr\/cvn172","article-title":"Decrease of peroxisome proliferator-activated receptor delta expression in cardiomyopathy of streptozotocin-induced diabetic rats","volume":"80","author":"Yu","year":"2008","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.lfs.2020.117843_bb0980","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/456042","article-title":"Doxorubicin-induced cardiac toxicity is mediated by lowering of peroxisome proliferator-activated receptor \u03b4 expression in rats","volume":"2013","author":"Chen","year":"2013","journal-title":"PPAR Res."},{"key":"10.1016\/j.lfs.2020.117843_bb0985","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jacc.2014.06.1167","article-title":"Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities","volume":"64","author":"Vejpongsa","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.lfs.2020.117843_bb0990","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.12688\/f1000research.15190.1","article-title":"Protecting the heart in cancer therapy","volume":"7","author":"Finet","year":"2018","journal-title":"F1000Research"},{"key":"10.1016\/j.lfs.2020.117843_bb0995","first-page":"18","article-title":"Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors","volume":"5","author":"Bansal","year":"2019","journal-title":"Cardiooncology"},{"key":"10.1016\/j.lfs.2020.117843_bb1000","doi-asserted-by":"crossref","DOI":"10.1002\/ehf2.12695","article-title":"Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS-ONE trial","author":"Meessen","year":"2020","journal-title":"ESC Heart Failure"},{"key":"10.1016\/j.lfs.2020.117843_bb1005","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s12012-007-0023-3","article-title":"Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?","volume":"7","author":"Hasinoff","year":"2007","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.lfs.2020.117843_bb1010","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1158\/0008-5472.CAN-07-1649","article-title":"Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane","volume":"67","author":"Lyu","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2020.117843_bb1015","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.2217\/fon-2018-0210","article-title":"Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling","volume":"14","author":"Reichardt","year":"2018","journal-title":"Future Oncol."},{"key":"10.1016\/j.lfs.2020.117843_bb1020","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ejphar.2017.10.043","article-title":"Molecular mechanism of doxorubicin-induced cardiomyopathy -an update","volume":"818","author":"Renu","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.lfs.2020.117843_bb1025","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.phrs.2017.03.016","article-title":"Doxorubicin targets multiple players: a new view of an old problem","volume":"127","author":"Cappetta","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.lfs.2020.117843_bb1030","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.critrevonc.2016.10.011","article-title":"Cancer treatment induced metabolic syndrome: improving outcome with lifestyle","volume":"108","author":"Westerink","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.lfs.2020.117843_bb1035","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12967-019-1850-2","article-title":"Key metabolic parameters change significantly in early breast cancer survivors: an explorative PILOT study","volume":"17","author":"Fredslund","year":"2019","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.lfs.2020.117843_bb1040","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.febslet.2012.11.019","article-title":"Doxorubicin treatment inhibits PPAR\u03b3 and may induce lipotoxicity by mimicking a type 2 diabetes-like condition in rodent models","volume":"587","author":"Arunachalam","year":"2013","journal-title":"FEBS Lett."},{"key":"10.1016\/j.lfs.2020.117843_bb1045","first-page":"835","article-title":"Insulin dependent diabetes mellitus induced by chemotherapy and granulocyte, macrophage--colony stimulating factor","volume":"47","author":"Geetha","year":"1999","journal-title":"J. Assoc. Physicians India"},{"key":"10.1016\/j.lfs.2020.117843_bb1050","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1203\/00006450-200202000-00020","article-title":"Serum lipid and fatty acid profiles in adriamycin-treated rats after administration of L-carnitine","volume":"51","author":"Hong","year":"2002","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.lfs.2020.117843_bb1055","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3389\/fphys.2016.00323","article-title":"Doxorubicin induces inflammatory modulation and metabolic dysregulation in diabetic skeletal muscle","volume":"7","author":"Supriya","year":"2016","journal-title":"Front. Physiol."},{"key":"10.1016\/j.lfs.2020.117843_bb1060","doi-asserted-by":"crossref","DOI":"10.1002\/jcsm.12104","article-title":"Doxorubicin caused severe hyperglycaemia and insulin resistance, mediated by inhibition in AMPK signalling in skeletal muscle","author":"de Lima Junior","year":"2016","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"10.1016\/j.lfs.2020.117843_bb1065","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s13105-012-0200-0","article-title":"Tissue retention of doxorubicin and its effects on cardiac, smooth, and skeletal muscle function","volume":"69","author":"Hayward","year":"2013","journal-title":"J. Physiol. Biochem."},{"key":"10.1016\/j.lfs.2020.117843_bb1070","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.2741\/3460","article-title":"Targeting the AMPK pathway for the treatment of type 2 diabetes","volume":"14","author":"Viollet","year":"2009","journal-title":"Front. Biosci."},{"key":"10.1016\/j.lfs.2020.117843_bb1075","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/toxsci\/kfw096","article-title":"Mechanisms of doxorubicin toxicity in pancreatic \u03b2-cells","volume":"152","author":"Heart","year":"2016","journal-title":"Tox. Sci."},{"key":"10.1016\/j.lfs.2020.117843_bb1080","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s40261-018-0645-1","article-title":"Impact of Anthracyclines on diabetes mellitus development in B-cell lymphoma patients: a nationwide population-based study","volume":"38","author":"Teng","year":"2018","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.lfs.2020.117843_bb1085","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1467-789X.2010.00805.x","article-title":"Weight gain in breast cancer survivors: prevalence, pattern and health consequences","volume":"12","author":"Vance","year":"2011","journal-title":"Obes. Rev."},{"key":"10.1016\/j.lfs.2020.117843_bb1090","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s12885-017-3242-4","article-title":"Weight change during chemotherapy in breast cancer patients: a meta-analysis","volume":"17","author":"van den Berg","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lfs.2020.117843_bb1095","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/1078155214551315","article-title":"Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer","volume":"22","author":"Bicakli","year":"2016","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.lfs.2020.117843_bb1100","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1053\/j.seminoncol.2013.09.011","article-title":"Energy balance and metabolism after cancer treatment","volume":"40","author":"Tonorezos","year":"2013","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.lfs.2020.117843_bb1105","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2001.19.9.2381","article-title":"Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy","volume":"19","author":"Demark-Wahnefried","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2020.117843_bb1110","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1200\/JCO.1999.17.1.120","article-title":"Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis","volume":"17","author":"Goodwin","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2020.117843_bb1115","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/NCC.0b013e3182a40e6d","article-title":"The development of the metabolic syndrome and insulin resistance after adjuvant treatment for breast cancer","volume":"37","author":"Guinan","year":"2014","journal-title":"Cancer Nurs."},{"key":"10.1016\/j.lfs.2020.117843_bb1120","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/cncr.30104","article-title":"An observational study to examine changes in metabolic syndrome components in patients with breast cancer receiving neoadjuvant or adjuvant chemotherapy","volume":"122","author":"Dieli-Conwright","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.lfs.2020.117843_bb1125","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/cam4.1911","article-title":"Effect of chemotherapy and aromatase inhibitors in the adjuvant treatment of breast cancer on glucose and insulin metabolism - a systematic review","volume":"8","author":"Buch","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.lfs.2020.117843_bb1130","first-page":"1747","article-title":"Exercise after diagnosis and metabolic syndrome among breast cancer survivors: a report from the Shanghai Breast Cancer Survival Study","volume":"24","author":"Bao","year":"2013","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.lfs.2020.117843_bb1135","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1158\/0008-5472.CAN-15-3307","article-title":"Exercise and prognosis on the basis of clinicopathologic and molecular features in early-stage breast cancer: the LACE and pathways studies","volume":"76","author":"Jones","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2020.117843_bb1140","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1200\/JCO.2015.61.1095","article-title":"Results of the exercise and nutrition to enhance recovery and good health for you (ENERGY) trial: a behavioral weight loss intervention in overweight or obese breast cancer survivors","volume":"33","author":"Rock","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2020.117843_bb1145","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41523-017-0040-8","article-title":"Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design","volume":"3","author":"Ligibel","year":"2017","journal-title":"NPJ Breast Cancer"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320520305932?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320520305932?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T20:38:08Z","timestamp":1758400688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320520305932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":229,"alternative-id":["S0024320520305932"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2020.117843","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of metabolic diseases in cardiotoxicity associated with cancer therapy: What we know, what we would know","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2020.117843","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117843"}}